$162.69−4.18 (−2.50%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD
$163.55+0.86 (+0.53%)
After hours: Nov 17, 2026, 6:06 PM ET
Revolution Medicines (RVMD) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
Sources Company filings FilingsHow we compute thisNot investment advice
4 figures withheld by our checks. Each blank figure names its reason.
Business engineChoppy: revenue is 67% below its peak (through FY23), net margin −3768.3%. Worth your attention in FY25: Share count (+161.1%) and Capex step-up ($16.0M). Both visible in the receipts below.
The four lines that matter · FY21–FY25
Revenue ($M)—
0.0
FY21→FY25CAGR —
Net income ($M)▼88.5%
−1,131.3
FY21→FY25CAGR —
Free cash flow ($M)▼60.9%
−913.7
capex stepped upCAGR —
Diluted EPS▼66.2%
−5.95
FY21→FY25CAGR —
What the receipts whisper · what a headline number hides
Share count
+161.1%
72.8mn → 190.1mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
Capex step-up
$16.0M
▲55% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
What the income statement says · FY21–FY25
Where every revenue dollar goes · FY25 ($M)
Margin trend · direction beats level Gross Operating Net
The receipt · income statement · FY21–FY25 USD thousands except per-share & ratios · hover a line for its definition
USD thousands except per-share & ratios
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 197,559.0 | 0.0 | 0.0 | 11,580.0 | 35,380.0 | 29,390.0 | — | — |
Cost of revenue | 327.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | 197,232.0 | 0.0 | 0.0 | —A | —A | 29,390.0 | — | — |
Research & development | 1,450,919.0 | 987,332.0 | 592,225.0 | 423,144.0 | 253,073.0 | 186,948.0 | ▲66.7% | +51.6% |
Selling, general & admin | 431,442.0 | 195,037.0 | 97,299.0 | 75,621.0 | 40,586.0 | 30,450.0 | ▲100.5% | +59.1% |
Total operating expenses | 1,882,361.0 | 1,182,369.0 | 689,524.0 | 498,765.0 | 293,659.0 | 217,398.0 | ▲71.5% | +52.7% |
Operating incomefeeds ROC rank | −1,685,129.0 | −1,182,369.0 | −689,524.0 | −487,185.0 | −258,279.0 | −188,008.0 | ▼71.5% | — |
Other income, net | −187,760.0 | 51,068.0 | 88,678.0 | 47,294.0 | 9,154.0 | 917.0 | — | — |
Pretax income | −1,872,889.0 | −1,131,301.0 | −600,846.0 | −439,891.0 | −249,125.0 | −187,091.0 | ▼88.3% | — |
Income tax | — | 0.0 | −753.0 | −3,524.0 | −420.0 | 0.0 | — | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −1,870,536.0 | −1,131,301.0 | −600,093.0 | −436,367.0 | −248,705.0 | −187,091.0 | ▼88.5% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −9.15 | −5.95 | −3.58 | −3.86 | −3.08 | −2.57 | ▼66.2% | — |
Diluted shares (mn) | 214.95 | 190.13 | 167.74 | 113.15 | 80.63 | 72.81 | ▲13.3% | +27.1% |
| Margins | ||||||||
Gross margin99th pct in Healthcare | 99.8% | — | — | —A | —A | 100.0% | — | — |
Operating margin | −853.0% | — | — | −4207.1% | −730.0% | −639.7% | — | — |
Net margin1st pct in Healthcare | −946.8% | — | — | −3768.3% | −703.0% | −636.6% | — | — |
† TTM = trailing four quarters through 2026-09-30.A Withheld: cost of revenue is not on file, so the gross margin is not measured.
3 more years of statements and CSV export are on Premium.Premium · $119/yr · 7-day trial · cancel anytimeUnlock with Premium →
These lines feed the tenet checklists: see which gates passTenets →Margins & returns continue as sector-ranked ratiosStatistics →
Annual report filed 2026-02-25 · view filings on SEC EDGAR ↗ · reported currency USD · as-filed figures may be later restated.
Statements normalized in our fundamentals DB · Not investment advice.
Statements normalized in our fundamentals DB · Not investment advice.
Annual and quarterly statements as filed, normalized into one comparable shape · Not investment advice.

